Articles

Hilleman Laboratories is committed to developing high impact, affordable vaccines for people in developing countries in an innovative and sustainable manner.

Meeting India’s immunisation goals

This requires sustainable use of resources, timely execution of strategies and total participation from all stakeholders


Unleashing the potential of technology in intelligent vaccine management


Rapid processes for purification of capsular polysaccharides from Neisseria meningitidis serogroups A and C


Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths


Synthesis of a tetrasaccharide and its glycoconjugate corresponding to the capsular polysaccharide of Neisseria meningitidis serogroup X and its immunochemical studies


A Forgotten Pioneer of Vaccines


Making New Vaccines Affordable

Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines (Lancet 2011; 378: 1885–93)


JSTOR: The Journal of Infectious Diseases, Vol. 174 (Sep., 1996), pp. S118-S124

Rotavirus infection produces a serious health burden in the United States, causing an estimated > 100,000 hospitalizations and >100 deaths annually.